Qiagen Shares Slide, Digene's Surge on Acquisition News | GenomeWeb
NEW YORK (GenomeWeb News) - Shares in Qiagen slid more than 10 percent to $15.48 in afternoon trading following news that it plans to acquire Digene for $61.50 a share, or around $1.6 billion.
 
Digene’s shares, meanwhile, were up 27 percent at $56.70 in afternoon trading.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.